Company intelligence / Profile preview

Jenga Biosciences

Carmel, Indiana, United States

Ownership: Private
Development stage: Other

Overview

JEN-101, a locally injected fully canine IL-12 complexed with aluminum hydroxide, showed potent biological activity and good safety in an exploratory canine melanoma study; at the pre-clinical stage with preliminary evidence for benefit in dogs with cancer[4][5].

Therapeutic areas: Oncology
Modalities: CytokineBiologic
Industry: Veterinary

Partnerships

Ankyra Therapeutics (exclusive worldwide license for JEN-101 development and commercialization)

Beyond the preview

Go deeper on Jenga Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jenga Biosciences.

Explore the full profile